Objective: To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with the King\u27s Clinical Staging System, and cognitive and behavioral change, measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Methods: A large multicenter observational cohort of 161 cross-sectional patients with ALS and 80 healthy matched controls were recruited across 3 research sites (Dublin, Edinburgh, and London). Participants were administered the ECAS and categorized into independent groups based on their King\u27s clinical disease stage at time of testing. Results: Significant differences were observed between patients and controls on all subtests of the ECAS except for visuospatial functioni...
Background: A cognitive impairment, ranging from frontotemporal dementia (FTD) to milder forms of dy...
International audienceObjectives: (1) Adapt the ECAS into Greek, validate it in ALS patients and com...
Cognitive impairment is present in approximately 30% of patients with amyotrophic lateral sclerosis ...
Objective To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS)...
ObjectiveTo assess the association of the degree of severity of motor impairment to that of cognitiv...
This study presents the Edinburgh Cognitive and Behavioural ALS Screen (ECAS), developed for ALS pat...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the...
Objective. To evaluate longitudinal cognitive/behavioral change over 12 months in participants enrol...
ObjectiveTo evaluate longitudinal cognitive/behavioral change over 12 months in participants enrolle...
Background: Amyotrophic Lateral Sclerosis is a multi-system disease that also affects cognition and ...
BackgroundTo prospectively evaluate the progression of cognitive-behavioral function in amyotrophic ...
doi:https://doi.org/10.1080/21678421.2017.1407794Background: Cognitive impairment affects approximat...
Emerging evidence shows that cognitive deficits associated with frontal lobe dysfunction occur from ...
Brief screening tools that detect and differentiate patients with amyotrophic lateral sclerosis and ...
Background: A cognitive impairment, ranging from frontotemporal dementia (FTD) to milder forms of dy...
International audienceObjectives: (1) Adapt the ECAS into Greek, validate it in ALS patients and com...
Cognitive impairment is present in approximately 30% of patients with amyotrophic lateral sclerosis ...
Objective To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS)...
ObjectiveTo assess the association of the degree of severity of motor impairment to that of cognitiv...
This study presents the Edinburgh Cognitive and Behavioural ALS Screen (ECAS), developed for ALS pat...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the...
Objective. To evaluate longitudinal cognitive/behavioral change over 12 months in participants enrol...
ObjectiveTo evaluate longitudinal cognitive/behavioral change over 12 months in participants enrolle...
Background: Amyotrophic Lateral Sclerosis is a multi-system disease that also affects cognition and ...
BackgroundTo prospectively evaluate the progression of cognitive-behavioral function in amyotrophic ...
doi:https://doi.org/10.1080/21678421.2017.1407794Background: Cognitive impairment affects approximat...
Emerging evidence shows that cognitive deficits associated with frontal lobe dysfunction occur from ...
Brief screening tools that detect and differentiate patients with amyotrophic lateral sclerosis and ...
Background: A cognitive impairment, ranging from frontotemporal dementia (FTD) to milder forms of dy...
International audienceObjectives: (1) Adapt the ECAS into Greek, validate it in ALS patients and com...
Cognitive impairment is present in approximately 30% of patients with amyotrophic lateral sclerosis ...